Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
NOG-associated tarsal-carpal coalition syndrome is an autosomal dominant skeletal disorder characterized by congenital fusion of carpal and tarsal bones leading to hindfoot varus, forefoot supination, pain, and gait disturbances. Initial descriptions include a sporadic 10-year-old female with bilateral foot varus requiring tailored surgical management (PMID:25799911) and a multigenerational Indian family (mother and two children) with similar phenotypes in which Sanger sequencing identified a novel heterozygous missense variant c.611G>A (p.Arg204Gln) in NOG (PMID:29159868). Only six NOG mutations have been reported in TCC to date, underscoring the rarity of this condition.
Genetic evidence for NOG in TCC is limited, comprising three affected members segregating the c.611G>A (p.Arg204Gln) allele in a single kindred (PMID:29159868). Functional studies demonstrate that NOG missense mutations act as hypomorphic alleles, reducing the secretion of noggin dimers and diminishing BMP antagonism in vitro, consistent with a dosage-dependent mechanism of joint fusion (PMID:11562478). Additional segregation and functional data are needed to reach higher ClinGen validity. Key take-home: Heterozygous NOG variants should be considered in the genetic evaluation of individuals with tarsal-carpal coalition syndrome for accurate diagnosis and management.
Gene–Disease AssociationLimited4 probands (1 sporadic, 3 familial) with clinical TCC and heterozygous NOG variants; functional concordance Genetic EvidenceLimited3 individuals with segregating heterozygous NOG c.611G>A (p.Arg204Gln) variant (PMID:29159868) Functional EvidenceModerateIn vitro assays show hypomorphic NOG missense mutations reduce noggin secretion and BMP antagonism (PMID:11562478) |